Skip to content

Modified Periosteal Tissue Graft vs Collagen Matrix for Soft Tissue Augmentation Around Implants: A Comparative Study

Modified Vascularized Interpostional Periosteal Connective Tissue Graft Versus Xenogeneic Collagen Matrix for Soft Tissue Augmentation Around Implant in Esthetic Zone (Comparative Study)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06808243
Enrollment
20
Registered
2025-02-05
Start date
2024-01-01
Completion date
2024-12-30
Last updated
2025-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dental, Implant

Keywords

implant, connective tissue graft, xenogenic membrane

Brief summary

This clinical trial aims to evaluate the effectiveness of the Modified Vascularized Interpositional Periosteal Connective Tissue Graft (mVIP-CTG) compared to Xenogeneic Collagen Matrix (XCM) around immediate implant in esthetic zone . This study will assess outcomes such as keratinized tissue thickness, keratinized tissue width, pink esthetic score and radiographic buccal cortex thickness over a defined follow-up period. By comparing mVIP-CTG to XCM, the study seeks to determine which method provides superior clinical and aesthetic results for best soft tissue augmentation

Detailed description

This study investigates two surgical techniques for managing peri-implant soft tissue deficiencies: the Modified Vascularized Interpositional Periosteal Connective Tissue Graft (VIP-CTG) and the Xenogeneic Collagen Matrix (XCM). Peri-implant soft tissue deficiencies, characterized by inadequate tissue volume or recession around dental implants, can lead to complications such as implant exposure, sensitivity, and aesthetic concerns. Conventional treatment methods aim to enhance soft tissue volume and improve the aesthetic and functional outcomes of implants. The mVIP-CTG approach utilizes autogenous pedicle grafts to improve tissue thickness and width, potentially enhancing soft tissue integration and thickness around immediate implants. In contrast, XCM is a xenogenic membrane offering a minimally invasive alternative substitute for soft tissue regeneration. The study design includes randomized assignment of participants to either the mVIP-CTG group or XCM group, with standardized surgical and follow-up protocols. Primary and secondary outcomes will include peri-implant soft tissue thickness, keratinized tissue width, pink esthetic score, and radiographic buccaal cortex thickness. Statistical analysis will evaluate the comparative effectiveness of both techniques in promoting peri-implant soft tissue regeneration and aesthetic recovery.

Interventions

PROCEDUREconnective tissue graft

10 patients received mVIP-CTG

DEVICExenogenic collagen membrane

10 patients received XCM

Sponsors

Minia University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

- * systemically healthy * teeth indicated for extraction due to trauma or root fracture * periodontally healthy * Good oral health * Selected patients of both sexes are 20-40 years old.

Exclusion criteria

* parafunctional habits * smoking, alcoholism * pregnancy * lactation * untreated periodontal diseases

Design outcomes

Primary

MeasureTime frameDescription
keratinized tissue thicknessbaseline, 3 months, 6 monthsmeasurement of Kertinized tissue thickness around implant using endodontic file
keratinized tissue widthbaseline, 3 months and 6 monthsmeasurement of keratinized tissue width using graduated UNC-15 Probe
buccal cortex thicknessbaseline and 6 monthsmeasurement of buccal cortex thickness using CBCT

Secondary

MeasureTime frameDescription
pink esthetic scorebaseline and 6 monthsmeasurement of pink aesthetic using visual scale of pink asethetic score

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026